Patents by Inventor Carolyn A. Weigelt
Carolyn A. Weigelt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11618753Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.Type: GrantFiled: January 24, 2019Date of Patent: April 4, 2023Assignee: Bristol-Myers Squibb CompanyInventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
-
Publication number: 20200347071Abstract: The disclosure relates to compounds of formula I which are useful as kinase modulators including RIPK 1 modulation. The disclosure also provides methods of making and using the compounds for example in treatments related to necrosis or inflammation as well as other indications.Type: ApplicationFiled: January 24, 2019Publication date: November 5, 2020Inventors: Scott Hunter Watterson, Murugaiah Andappan Murugaiah Subbaiah, Carolyn Diane Dzierba, Hua Gong, Jason M. Guernon, Junqing Guo, Amy C. Hart, Guanglin Luo, John E. Macor, William J. Pitts, Jianliang Shi, Brian Lee Venables, Carolyn A. Weigelt, Yong-Jin Wu, Zhizhen Barbara Zheng, Sing-Yuen Sit, Jie Chen
-
Patent number: 10435369Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: November 8, 2017Date of Patent: October 8, 2019Assignee: Bristol-Myers Squibb CompanyInventors: David Marcoux, Myra Beaudoin Bertrand, T. G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G. Batt
-
Publication number: 20180127368Abstract: There are described ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: November 8, 2017Publication date: May 10, 2018Inventors: David Marcoux, Myra Beaudoin Bertrand, T.G. Murali Dhar, Michael G. Yang, Zili Xiao, Hai-Yun Xiao, Yeheng Zhu, Carolyn A. Weigelt, Douglas G Batt
-
Publication number: 20180002358Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: September 12, 2017Publication date: January 4, 2018Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Patent number: 9815859Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: May 6, 2016Date of Patent: November 14, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A. M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Patent number: 9771320Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 5, 2015Date of Patent: September 26, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Zhonghui Lu, Ananta Karmakar, Arun Kumar Gupta, Carolyn A. Weigelt
-
Patent number: 9708253Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: GrantFiled: January 5, 2015Date of Patent: July 18, 2017Assignee: Bristol-Myers Squibb CompanyInventors: Jingwu Duan, T. G. Murali Dhar, Bin Jiang, Ananta Karmakar, Arun Kumar Gupta, Zhonghui Lu, Carolyn A. Weigelt
-
Publication number: 20160326195Abstract: There are described ROR? modulators of the formula (I), and formula (II) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: May 6, 2016Publication date: November 10, 2016Inventors: Jingwu Duan, T.G. Murali Dhar, David Marcoux, Qing Shi, Douglas G. Batt, Qingjie Liu, Robert J. Cherney, Lyndon A.M. Cornelius, Anurag S. Srivastava, Myra Beaudoin Bertrand, Carolyn A. Weigelt
-
Publication number: 20160326104Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu DUAN, T.G.Murali DHAR, Bin JIANG, Ananta KARMAKAR, Arun Kumar GUPTA, Zhonghui LU, Carolyn A. WEIGELT
-
Publication number: 20160326103Abstract: Described are ROR? modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.Type: ApplicationFiled: January 5, 2015Publication date: November 10, 2016Inventors: Jingwu Duan, T.G. Murali Dhar, Bin Jiang, Zhonghui Lu, Ananta Karmakar, Arun Kumar Gupta, Carolyn A. Weigelt